TITLE

REMS accompanies launch of new melanoma drug

PUB. DATE
April 2011
SOURCE
Reactions Weekly;4/16/2011, Issue 1347, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of Yervoy (ipilimumab) by the U.S. Food and Drug Administration (FDA) on March 26, 2011 for the treatment of unresectable or metastatic melanoma and the launching of a Risk Evaluation and Mitigation Strategy (REMS) by the drug's developer Bristol-Myers Squibb (BMS) to inform patients and providers about associated safety risks.
ACCESSION #
60073917

 

Related Articles

  • FDA approves Tafinlar, Mekinist for treatment of metastatic melanoma.  // Hem/Onc Today;6/25/2013, Vol. 14 Issue 12, p26 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of dabrafenib and trametinib for treatment of melanoma patients.

  • FDA APPROVES FIRST TARGETED COMBINATION THERAPY FOR MELANOMA.  // Skin Cancer Foundation Journal;2014, Vol. 32, p11 

    The article reports on the U.S. Food and Drug Administration's approval of two drugs, dabrafenib and trametinib, as targeted combination therapy for advanced melanoma.

  • First oncolytic virus vaccine for advanced melanoma. MULLER, ALLISON A. // Pharmacy Today;Dec2015, Vol. 21 Issue 12, p32 

    The article focuses on the drug talimogene laherparepvec, the first oncolytic virus therapy approved by the U.S. Food and Drug Administration (FDA) for treatment of recurrent melanoma.

  • Xalkori and Zelboraf Prove Efficiency of RxDx Strategy. Morrison, Trista // BioWorld Insight;9/6/2011, Vol. 19 Issue 36, p1 

    The article presents the author's comments on the approval of melanoma drug Zelboraf, and lung cancer drug Xalkori, by the U.S. Federal Drug Administration (FDA). The author states that though several drugs languish in clinical trials for a decade, Zelboraf and Xalkori moved quickly, because...

  • Medarex: Ipilimumab Misses Endpoint In Melanoma Study. Osborne, Randall // BioWorld Today;12/12/2007, Vol. 18 Issue 240, p1 

    The article reports that Medarex Inc. and partner Bristol-Myers Squibb Co. plan to pursue a biologics license application in 2008 for the melanoma drug ipilimumab, despite missed primary endpoints in three pivotal trials, including one conducted under a special protocol assessment with the U.S....

  • FDA actions. Elliott, William T. // Infectious Disease Alert;Oct2011 Pharmacology Watch, p2 

    The article provides updates on the U.S. Food and Drug Administration (FDA) approvals including fixed-dose combination pill for HIV-infected patients, brentuximab vedotin to treat Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma and vemurafenib for treating metastatic and...

  • Plexxikon's Speedy Zelboraf Work Helped by Diagnostic. Boggs, Jennifer // BioWorld Today;8/18/2011, Vol. 22 Issue 160, p1 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of antimelanoma drug Zelboraf (vemurafenib) manufactured by Plexxikon Inc. The speedy approval of the drug can be attributed to the utilization of companion diagnostics in the development and commercialization of...

  • Medarex/Britol-Myers: another setback in melanoma.  // PharmaWatch: Cancer;Jun2008, Vol. 7 Issue 6, p13 

    The author reflects on the delay in the submission of ipilimumab's Biologics License application of Medarex Inc. and Bristol-Myers. According to the author, the setback following the request by the U.S. Food and Drug Administration (FDA) for additional survival data could bring forth worries for...

  • FDA approves two melanoma drugs.  // Dermatology Times;Jun2013, Vol. 34 Issue 6, p18 

    The article reports that two melanoma drugs and a companion diagnostic were approved by the U.S. Food and Drug Administration (FDA). The two drugs, Tafinlar (dabrafenib) and Mekinist (trametinib) are approved as single agents, not as a combination treatment. Side effects reported by patients who...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics